MedPath

The Efficacy of Chlorhexidine Gluconate Gel Dressing in Preventing Surgical Drain Site Infection

Not Applicable
Withdrawn
Conditions
Drain Site Complication
Interventions
Device: 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing
Registration Number
NCT04656145
Lead Sponsor
NYU Langone Health
Brief Summary

This study aims to evaluate if the application of chlorhexidine gluconate dressing on surgical drain sites can decrease drain site infection vs the standard of care (dry, sterile gauze).

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. Age 18 years or older
  2. Receiving two surgical drains during one of the following types of operative procedures: breast reduction, breast augmentation, abdominoplasty, panniculectomy, brachioplasty, thigh lift, lower body lift, belt lipectomy, back latissimus dorsi reconstruction, bilateral breast reconstruction, or bilateral chest reconstruction. These drains may be in fairly close proximity to one another but they must emerge from different areas of the skin, that way they can be considered to be located in two different sites.
Exclusion Criteria
  1. Concurrent implantation of any foreign objects, such as a breast implant
  2. Patients who receive postoperative antibiotics without a suspected or identified site of infection
  3. Subjects allergic to or hypersensitive to chlorhexidine gluconate. Before enrolling in the study, patients will be asked about previous exposure to chlorhexidine products and about their allergies. Those with potential allergic or adverse reaction to chlorhexidine will be excluded from the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Chlorhexidine Gluconate Gel Dressing3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement DressingAll subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to receive the intervention.
Primary Outcome Measures
NameTimeMethod
Change in Erythema MeasurementDay 0, up to Month 6

Drain site erythema will be measured with a ruler, in millimeters.

Number of participants in each category of skin induration (flat, soft, or firm)up to Month 6

2. Induration of skin will be measured by palpation of the skin around the drain by the clinician. This will be measured by assessing whether skin is flat, soft, or firm.

Total amount of drainage from drain siteUp to Month 6

Amount of drainage from drain site will be measured in cubic centimeters.

Number of participants who experience pain post-opUp to Month 6

5. Pain will be measured by asking patients if they experience pain (yes or no) when the clinician presses on the drain site.

Number of participants in each category of quality of drainage (serous, sanguineous, or purulent)Day 0, up to Month 6

Quality of drainage will be assessed by measuring thickness of drainage. Thickness of drainage will be measured as serous, sanguineous, or purulent.

Change in distance between skin changes and normal looking skinDay 0, up to Month 6

Extent of skin changes is measured using a ruler, in millimeters, to calculate the distance between skin changes and normal looking skin.

Secondary Outcome Measures
NameTimeMethod
Number of participants displaying presence of hematomaup to Month 6
Number of participants displaying sterility of seromaup to Month 6

Sterility of seroma will be measured by assessing whether the serous collection of fluid has absence of infection.

Number of participants displaying signs of wound infectionup to Month 6

Measures of wound infection will be assessed by documenting any signs of cellulitis or abscess around the drain.

Antibiotic prescription rateup to Month 6

This will be measured as the number of days that patients are prescribed antibiotics.

Trial Locations

Locations (1)

NYU Langone Health

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath